Beyond CNV: leveraging SNP microarrays in cancer

Dr. Stephen Moore, MBA, MS, PhD, FACMG

Associate Professor of Molecular and Medical Genetics at Oregon Health and Science University, Portland, Oregon, USA & Director of the Clinical Cytogenetics and Clinical Molecular Diagnostics labs of the OHSU Knight Diagnostics Labs, Portland, Oregon, USA

OGT's chromosomal microarrays are a backbone of genomics laboratories and are regularly used in oncology research. Often the focus is the robust detection of oligonucleotide components, i.e., copy number changes, including exon-level.

In this presentation, Dr. Stephen Moore will share his experience utilising OGT's CytoSure^® chromosomal microarrays in various tumour types. Specifically, he will highlight the different applications of the single nucleotide polymorphism (SNP) track beyond oligonucleotides confirmation.

Recent publications from the speaker

1. A novel heptasomy 21 associated with complete loss of heterozygosity and loss of function RUNX1 mutation in acute myeloid leukemia
2. Adult acute myeloid leukemia patients with NUP98 rearrangement have frequent cryptic translocations and unfavorable outcome
3. Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion
   

Disclaimer

This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the presenters individually and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented.

CytoSure^®: For research use only; not for use in diagnostic procedures.